Swiftmerge Acquisition Corp. Takes HDL Therapeutics Public in $400 Million Transaction
On August 11, Swiftmerge Acquisition Corp., a West Vancouver-based special purpose acquisition company, announced that it was taking HDL Therapeutics Inc. public through a merger. HDL Therapeutics is a biotech innovator, focused on developing first-in-class treatments for intractable cardiovascular and neurovascular diseases using the company’s proprietary technology platform. The holders of the outstanding HDL Therapeutics preferred stock and common stock will receive a combination of cash and equity in Swiftmerge totaling $400 million. The business combination values the combined company at approximately $480 million. Upon closing of the merger, Swiftmerge will change its... Read More »
Eli Lilly to Acquire Boston-Based Biotech Versanis
Eli Lilly and Company and Versanis announced on July 14 a definitive agreement for Lilly to acquire Versanis. Under the terms of the agreement, Versanis shareholders could receive up to $1.925 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain development and sales milestones. Versanis is a Boston-based, clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Eli Lilly and Company is headquartered in Indianapolis,... Read More »
Baudax Bio Acquires TeraImmune
Baudax Bio, Inc. announced on June 30 that it acquired TeraImmune, Inc. TeraImmune is a privately held biotechnology company working on cell therapies for autoimmune diseases. Key technical assets of TeraImmune include expansion of human regulatory T cells in vitro and receptors targeting pathological immune cells (T cell/ B cell/ antigen presenting cell). Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The company has multiple non-opioid therapeutics in clinical development for the treatment of pain conditions and is currently promoting their lead product, ANJESO™, indicated for use in adults for the... Read More »
Talaris Therapeutics Merges with Tourmaline Bio
Talaris Therapeutics, Inc. announced on June 22 that it entered an agreement to merge with Tourmaline Bio, Inc. According to data captured in the LevinPro HC database, this transaction represents the 76th Biotechnology transaction of 2023. Talaris stockholders are expected to receive $3.43 per Talaris share for a total price of more than $144.62 million. Tourmaline stockholders are expected to own 78.7% of the combined company and Talaris stockholders are expected to own 21.3% of the combined company, each on a fully diluted basis. Talaris anticipates making a cash dividend of up to approximately $64.8 million to its stockholders prior to the closing of the Merger. Talaris Therapeutics is... Read More »
Pyxis Oncology Acquires Apexigen
Pyxis Oncology announced on May 24 that it acquired Apexigen, Inc. for $16 million. Founded in 2010, Apexigen, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology. Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates and immunotherapies. It is funded by the Longwood Fund, a Boston-based venture capital firm. This acquisition was announced nearly a year after Apexigen went public by a merger with Brookline Capital Acquisition Corp. According to data captured in the LevinPro HC database, this acquisition represents the 61st... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
